International Journal of Hematology and Oncology
She was treated with EM at 600 mg/day for 1 week. Just before receiving this therapy, her PC were 54×10 9 /L with no therapy. After 2 weeks and about 4 weeks, PC indicated 131×10 9 /L and 72×10 9 /L, respectively.
She was treated with EM at 600 mg/day for 1 week. Just before receiving this therapy, her PC were 54×109/L with no therapy. After 2 weeks and about 4 weeks, PC indicated 131×10 9 /L and 72×10 9 /L, respectively.
In 6 out of 7 patients treated with macrolides, PC increased after 1 or 2 weeks and decreased after about 4 weeks (Figure 1 ). And only in 1 patient, namely Case 1, PC did not increase and remained at the level of 20×10 9 /L ( Figure 1 ). In Case 4, 5, and 6, PC were higher just before taking macrolides than 1 or 3 months before catching a cold. Therefore, PC were thought not to be affected by a cold. As a result, it was suggested that macrolides really increased PC. However, in Case 2, 3, and 7, PC were lower just before taking macrolides than 1 or 3 months before catching a cold. Lower PC just before macrolide treatment and recovered PC 1 or 2 weeks after macrolide treatment might be associated with infection. Recovered PC in Case 2, 3 and 7, might be due to reaction after infection and/or effects of macrolides. After all, at least, in 3 cases, that is, Case 4, 5, and 6, macrolide treatment was thought to be effective, but temporary. Recent studies have suggested that ITP patients infected with HP can be successfully treated with above-mentioned eradication therapy. It is reported that eradication is only achieved in 15% of patients with CAM (1,000 mg/day) monotherapy. So the increased PC in Case 2 might be due to a reduction in the quantity of HP and/or a bacteriostatic effect of CAM, 4 including immunomodulatory effects of macrolides. Because macrolides have steroid-sparing effects via their influence on corticosteroid metabolism, not only immunomodulatory effects but also steroid-sparing effects might increase the PC in Case 3 and 5. Based on these results, ITP patients may benefit from short-term use of macrolides, when they undergo a simple operation such as a tooth extraction or their PC decrease after infection. But repeated short-term or long-term use of macrolides may promote the growth of drug-resistant bacteria, so these macrolides treatment for ITP should not be considered recommended therapies. Otsu et al. reported the effectiveness of a new macrolide which has immunomodulatory effects and no antibacterial effects. 5 So ITP patients will be able to benefit from this new macrolide treatment without the incidence of drug-resistant bacteria in the future.
